PAREXEL Expands CNS Capabilities

Article

Company News Release

PAREXEL enhances early phase clinical development offering for central nervous system studies.

Boston, MA-, June 17, 2008-PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it is expanding its clinical pharmacology capabilities in the Central Nervous System (CNS) therapeutic area. PAREXEL is enhancing existing services in early phase clinical development by adding pain modeling capabilities and combining traditional pharmacodynamic methods with relevant biomarkers, which are surrogate endpoints used to determine safety and efficacy signals.

"CNS diseases, which are reported to account for one third of the world's disease burden, include neurodegenerative diseases such as Alzheimer's and conditions characterized by chronic pain," said Michelle Middle, corporate vice president and worldwide head, clinical pharmacology, PAREXEL. "Our global team of clinical pharmacology experts with in-depth CNS expertise applies various methodologies and biomarkers to help clients make earlier and more effective decisions regarding CNS treatments, and advance this important and growing area of research."

PAREXEL's dedicated clinical pharmacology services directed at alleviation of pain and related symptoms use neuroscience biomarkers to enhance exploration of safety and efficacy and pharmacokinetic analysis. This expanded approach for a broad range of psychiatry, neuropsychopharmacology, neuroimaging, and neurophysiology clinical studies provides greater information about CNS treatments in early phase development. This expertise is aided by the ability to conduct studies with healthy volunteer and patient populations in a time-efficient manner.

PAREXEL, which is a top provider of expertise-based early phase development services from first-in-man to proof of concept, utilizes strategic locations, state-of-the-art technology, and highly qualified and experienced personnel to optimize time and cost savings for clients. PAREXEL's clinical pharmacology business has more than 550 beds, among the largest capacities worldwide. The company's Clinical Pharmacology Research Units are located in Baltimore, MD, and in Los Angeles and San Diego, CA in the United States; London, UK; Berlin, Germany; and Bloemfontein and George, South Africa. PAREXEL also provides early clinical development programs through a joint venture arrangement with Synchron Research based in India.

For more information about PAREXEL's international clinical pharmacology capabilities, visit: http://www.parexel.com/early_phase.html.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.